Sebetralstat

Last updated on: 25.04.2025

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).

Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Sebetralstat is an investigational oral plasma kallikrein inhibitor for the acute treatment of hereditary angioedema (HAE).

Pharmacodynamics (Effect)This section has been translated automatically.

Sebetralstat works in the treatment of hereditary angioedema (HAE) by targeting the kallikrein-kinin system (KKS) cascade and selectively inhibiting the plasma kallikrein that triggers HAE attacks. Sebetralstat is administered orally to treat HAE attacks on demand, i.e. at the first signs before the HAE attack fully develops. All currently approved on-demand treatment options require either intravenous or subcutaneous administration.

LiteratureThis section has been translated automatically.

Cohn DM et al. (2025) CRISPR-Based Therapy for Hereditary Angioedema. N Engl J Med 392:458-467.
Longhurst HJ et al. (2024) CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med 390:432-441.
Riedl MA et al. (2024) Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks. N Engl J Med 391:32-43.

Last updated on: 25.04.2025